These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34037215)

  • 1. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money.
    Morris GA; McNicol M; Boyle B; Donegan A; Dotson J; Michel HK; Maltz RM
    Inflamm Bowel Dis; 2022 Mar; 28(4):531-538. PubMed ID: 34037215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease.
    McNicol M; Abdel-Rasoul M; McClinchie MG; Morris GA; Boyle B; Dotson JL; Michel HK; Maltz RM
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):644-652. PubMed ID: 38334232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
    Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
    Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
    Armuzzi A; Bouhnik Y; Cummings F; Bettey M; Pieper B; Kang T
    Dig Liver Dis; 2020 Nov; 52(11):1259-1265. PubMed ID: 32601035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars in Inflammatory Bowel Disease.
    Buchner AM; Schneider Y; Lichtenstein GR
    Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.
    Meijboom RW; Gardarsdottir H; Egberts TCG; Giezen TJ
    BioDrugs; 2022 Jan; 36(1):27-39. PubMed ID: 34870802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
    Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
    Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey.
    Maltz RM; McClinchie MG; Boyle BM; McNicol M; Morris GA; Crawford EC; Moses J; Kim SC
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):616-621. PubMed ID: 36827968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.